Abstract:
Objective To study the anti-tumor effect of Indirubin-3'-monoxime combined with Nedaplatin(Nap) on the human esophageal cancer cell line EC-1,and to reveal its methanism. Methods Human esophageal cancer line EC-1 was treated
in vitroby Indirubin-3'-monoxime with or without Nap in various concertration. The cell growth was evaluated by MTT assay,cell cycle distribution were observed by flow cytometry,and the expression of apoptosis-related genes were analyzed by immunohistochemical staining method. Results Compared with Indirubin-3-'monoxime or Nap individual drug groups,Indirubin-3'-monoxime combined with Nap obviously increased the inhibitory rate of the human esophageal cancer cell line EC-1.In the groups treated by the combinatio of Indirubin-3'-monoxime and Nap, the cell cycle distribution was altered.In this case, the ratio of G
0/G
1 phase cell decreased,the G
2/M phase cell increased, the expression of following the treatment with Indirubin-3'-monoxime combined with Na,with Bcl-2 gene down-regulated,and the expression of Bax gene expression up-regulated. Conclusion Indirubin-3'-monoxime combined with Nap may obviously increase the inhibitory rate of the human esophageal cancer cell,and its mechanism may be to regulate cell cycle and to increase apoptosis-inducing effect which is regulated by several genes.